

Thoracic Aortic Aneurysms and Dissections (TAAD) Panel Genetic Testing

EviCore
By EVERNORTH

- This benefit/harm statement only applies to those jurisdictions that do not have Medicare guidance.
- Based upon the guidelines and evidence provided in the clinical policy, following EviCore's criteria for thoracic aortic aneurysms and dissections (TAAD) panel testing will ensure that testing will be available to those members most likely to benefit from a genetic diagnosis. For those not meeting criteria, it ensures alternate diagnostic strategies are considered. However, it is possible that some members who have the condition, but have non-standard features, will not receive an immediate approval for testing.